KindredBio has an exciting pipeline of high-value product candidates for cats, dogs, and horses in development.
Our disclosed candidates are outlined below, but we have multiple other undisclosed candidates under development as well.
Pipeline Snapshot
 |
|---|
| KIND-030 – Parvovirus in dogs
|
| IL31 Antibody – Atopic dermatitis in dogs
|
| IL4/13 SINK – Atopic dermatitis in dogs
|
| IL4R Antibody – Atopic dermatitis in dogs
|
| IL17 Antibody – Atopic dermatitis in dogs
|
| KIND-510a (feline recombiant epo) – Non-regenerative anemia in cats
|
| KIND-012 (dipyrone oral gel) – Control of fever in horses
|
| Anti-TNF Antibody – Inflammatory bowel disease in dogs
|
| KIND-014 – Equine gastric ulcers
|
| KIND-015 – Metabolic syndrome in horses
|
| Anti-TNF Antibody – Sick newborn foals
|
Other pipeline candidates in development (partial list) include KIND-bodies, IgE antibody, CD20 antibody, VEGF antibody, and Checkpoint Inhibitors.
Pipeline Disclaimer: This material is intended to provide investors with information about KindredBio’s clinical development pipeline and is not intended for promotional purposes.
Cats are not small dogs.
Cats are a unique species with distinct needs. Our feline family members deserve the same great care that our human family members receive.
Our dogs look to us.
Dogs experience many of the same diseases that humans do, including allergic, inflammatory, and autoimmune diseases, as well as cancer. We have a deep pipeline of novel pharmaceuticals and biologics in development specifically for dogs, their owners, and the veterinarians that care for them.
A horse’s success starts on the inside.
Veterinarians lack FDA-approved drugs to treat some of the most common health issues facing horses. At KindredBio, we believe our equine family members merit the same innovative medicines that we enjoy.
US-CORP-1900168 FEB-20
$10.87 
1.21 (12.53%)
1.21 (12.53%)
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
